FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
59.147,14 -470,21 (-0,79%)
Cullinan Therapeutics, Inc. (CGEM)
Dopo ore:
| Chiusura precedente | 27,58 |
| Aperto | 28,22 |
| Denaro | 28,27 x 200 |
| Lettera | 28,35 x 200 |
| Min-Max giorno | 27,91 - 29,25 |
| Intervallo di 52 settimane | 7,64 - 29,25 |
| Volume | |
| Media Volume | 698.752 |
| Capitalizzazione | 1,221B |
| Beta (5 anni mensile) | 0,33 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -3,69 |
| Prossima data utili | 09 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 33,14 |
GlobeNewswireCullinan Oncology to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced its participation in the following upcoming investor conferences: Nadim Ahmed, Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference. Mr. Ahmed’s presentation will be available on-demand beginning at 7:00 am ET on Monday, September 11,
- GlobeNewswire
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer (NSCLC) patients (REZILIENT-3) open to enrollment Initial monotherapy clinical data for CLN-619 presented at ASCO 2023 Annual Meeting; initiated monotherapy expansion cohorts in endometrial and cervical cancers First patient dosed in Phase 1 study of CLN-978 in relapsed/refractory (R/R) B Cell non-Hodgkin lymphoma (B-NHL) Cash and investment position of $512.1 million as of June 30, 2023 contin
- GlobeNewswire
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating CLN-978 for the treatment of relapsed/refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL). The study is an open-label, dose-escalation, dose-expansion, and first-in-human study designed to evaluate the safety, tolerability, ph
